Navigation Links
Added benefit of saxagliptin/metformin combination is not proven
Date:4/29/2013

The fixed combination of the drugs saxagliptin and metformin (Komboglyze) has been approved in Germany since November 2011 for the treatment of type 2 diabetes mellitus. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this fixed combination product offers an added benefit versus the current standard treatment. Such an added benefit cannot be derived from the dossier, however, as the manufacturer did not submit any relevant data.

Dual or triple combination therapy possible

The combination is an option for adult patients who do not benefit sufficiently from the commonly used drug metformin or who are already taking saxagliptin and metformin as individual tablets. It can also be used together with insulin if insulin and metformin are insufficient.

Glibenclamide or glimepiride as the appropriate comparator therapy

The Federal Joint Committee (G-BA) has specified metformin in combination with a sulfonylurea (glibenclamide or glimepiride) as the appropriate comparator therapy for saxagliptin/metformin. The triple combination therapy, i.e. saxagliptin/metformin and insulin, was to be compared with metformin and human insulin.

Dual combination: Manufacturer compared saxagliptin/metformin with glipizide

Regarding the dual combination therapy, the manufacturer deviated from the G-BA's specifications and submitted data from an approval study in which the patients in the control group did not receive glibenclamide or glimepiride, but another sulfonylurea, namely glipizide. However, this drug has no longer been approved in Germany since 2007. In addition, the manufacturer did not provide sufficient explanation in its dossier that glipizide is equivalent to the other two sulfonylureas.

Study on triple combination is unsuitable

Regarding the combination with insulin, the manufacturer submitted a study that directly compared saxagliptin/metformin and insulin with metformin und human insulin. But the results of this study cannot be used for the assessment of the added benefit.

The main reason for this is that the insulin therapy could not be tailored sufficiently to the individual patient in the first treatment phase: even though their current insulin therapy was insufficient, patients were neither supposed to change the insulin nor to adapt the dose. But to be able to draw conclusions about the added benefit, the combination of saxagliptin/metformin and insulin would have to be compared with other strategies for optimizing treatment, for example optimizing insulin use.

Not tailoring treatment to the individual patient does not meet the current standard of diabetological practice anyway. Instead, insulin therapy is optimized for the individual patient so that hyperglycaemia and hypoglycaemia do not occur in the first place. So in the study, insulin was not used in a way that would be necessary and appropriate in this indication.

Therefore, there are no study results for either of the two therapeutic indications of the fixed combination saxagliptin/metformin from which an added benefit could be derived.

G-BA decides on the extent of added benefit

The dossier assessment is part of the overall procedure for early benefit assessments supervised by the G-BA. After publication of the manufacturer's dossier and IQWiG's assessment, the G-BA conducts a commenting procedure, which may provide further information and result in a change to the benefit assessment. The G-BA then decides on the extent of the added benefit, thus completing the early benefit assessment.


'/>"/>

Contact: Anna-Sabine Ernst
presse@iqwig.de
49-022-135-6850
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Related medicine news :

1. Left Coast Marijuana Delivery Service Added To Top-Tier Dispensary Locator
2. BPA Added To California’s Toxic Chemicals List Making BPA-Free Dental Products from PureLife More Attractive
3. Astro-Clairvoyant Norah Guide With Premium Astrology Extends Blog Series With Newly Added Video Features
4. New Karlsson Vintage Wall Clocks Added at Contemporary Heaven
5. Innovative Medical Marijuana Growing Product added to PotLocator.com Lineup
6. Master Numerologist at Numerology Secret Added New Rave Reviews To His Testimonial Base
7. New Lines Added to the Arti & Mestieri Clocks Range at Contemporary Heaven US
8. Perampanel for epilepsy: No proof of added benefit
9. Added benefit of aclidinium bromide is not proven
10. Linagliptin: Once again, no proof of added benefit
11. New Wall Clocks Added to the Balvi Range at Contemporary Heaven
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... ... August 19, 2017 , ... DMG Productions, producers of the ... in an upcoming episode, slated to air fourth quarter 2017. Check your local ... Group; a company committed to supporting dentistry using the most technologically advanced restorative ...
(Date:8/19/2017)... ... August 18, 2017 , ... President ... of 2017, legislation that provides for greater public access to over-the-counter (OTC) hearing ... to access OTC hearing aids without being seen by a certified and licensed ...
(Date:8/19/2017)... ... 2017 , ... Praeclarus Press has launched a new ... the diversity of the breastfeeding mothers, using bright colors and contemporary themes. These ... are also available on tote bags, notepads, smartphone cases, clocks, and travel mugs. ...
(Date:8/19/2017)... Fla. (PRWEB) , ... August 19, 2017 , ... ... Taufiq Ahmed, M.D., has joined its Orlando location as an interventional pain management ... anesthesiology, a focus on the treatment of migraine headaches, and significant experience in ...
(Date:8/18/2017)... , ... August 18, 2017 , ... More than 20,000 ... Republic of Congo (DRC) thanks to an ambitious venture that conjoined the passions of ... the generous support of the Liberty community. These shoes will save lives from the ...
Breaking Medicine News(10 mins):
(Date:8/4/2017)... ROCKVILLE, Md. , Aug. 4, 2017 ... during or shortly after a physician/patient consult has long ... industry, and was a notable focus of the largest ...  This is according to healthcare market research firm Kalorama ... of care testing (POCT) offerings or related supplies and ...
(Date:8/2/2017)... 2, 2017  Life Flight Network and PeaceHealth Oregon Network ... patient care and operational efficiency for patients at hospitals in ... Cottage Grove , and Florence, ... and Life Flight Network work collaboratively to move patients who ... when a time sensitive emergency exists. ...
(Date:7/31/2017)... 7D Surgical, developer of ground breaking surgical navigation ... Surgical System to support its strategic sales plan in ... and Virginia.  7D Surgical has entered into an exclusive sales ... medical facilities within those markets. ... Spartan Medical Purchases ...
Breaking Medicine Technology: